메뉴 건너뛰기




Volumn 33, Issue 34, 2015, Pages 4032-4038

Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer

(17)  Kopetz, Scott a   Desai, Jayesh h   Chan, Emily b   Hecht, Joel Randolph c   O'Dwyer, Peter J a   Maru, Dipen a   Morris, Van a   Janku, Filip a   Dasari, Arvind a   Chung, Woonbook h   Issa, Jean Pierre J h   Gibbs, Peter g,j   James, Brian d   Powis, Garth d   Nolop, Keith B e   Bhattacharya, Suman f   Saltz, Leonard i  


Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; VEMURAFENIB; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; SULFONAMIDE;

EID: 84951810474     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.63.2497     Document Type: Article
Times cited : (562)

References (34)
  • 1
    • 18444374405 scopus 로고    scopus 로고
    • Mutations of the BRAF gene in human cancer
    • Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417:949-954, 2002
    • (2002) Nature , vol.417 , pp. 949-954
    • Davies, H.1    Bignell, G.R.2    Cox, C.3
  • 2
    • 38949131824 scopus 로고    scopus 로고
    • BRAF(E600) in benign and Malignant human tumours
    • Michaloglou C, Vredeveld LC, Mooi W.J., et al: BRAF(E600) in benign and malignant human tumours. Oncogene 27:877-895, 2008
    • (2008) Oncogene , vol.27 , pp. 877-895
    • Michaloglou, C.1    Vredeveld, L.C.2    Mooi, W.J.3
  • 3
    • 0030771387 scopus 로고    scopus 로고
    • Ras effectors and their role in mitogenesis and oncogenesis
    • Joneson T, Bar-Sagi D: Ras effectors and their role in mitogenesis and oncogenesis. J Mol Med (Berl) 75:587-593, 1997
    • (1997) J Mol Med (Berl) , vol.75 , pp. 587-593
    • Joneson, T.1    Bar-Sagi, D.2
  • 4
    • 84922949171 scopus 로고    scopus 로고
    • Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes
    • Sinicrope FA, Shi Q, Smyrk T.C., et al: Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology 148:88-99, 2015
    • (2015) Gastroenterology , vol.148 , pp. 88-99
    • Sinicrope, F.A.1    Shi, Q.2    Smyrk, T.C.3
  • 5
    • 84881640407 scopus 로고    scopus 로고
    • Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication
    • Lochhead P, Kuchiba A, Imamura Y., et al: Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst 105:1151-1156, 2013
    • (2013) J Natl Cancer Inst , vol.105 , pp. 1151-1156
    • Lochhead, P.1    Kuchiba, A.2    Imamura, Y.3
  • 6
    • 79958817037 scopus 로고    scopus 로고
    • Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer
    • Tran B, Kopetz S, Tie J., et al: Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 117:4623-4632, 2011
    • (2011) Cancer , vol.117 , pp. 4623-4632
    • Tran, B.1    Kopetz, S.2    Tie, J.3
  • 7
    • 77956030786 scopus 로고    scopus 로고
    • Inhibition of mutated, activated BRAF in metastatic melanoma
    • Flaherty KT, Puzanov I, Kim K.B., et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819, 2010
    • (2010) N Engl J Med , vol.363 , pp. 809-819
    • Flaherty, K.T.1    Puzanov, I.2    Kim, K.B.3
  • 8
    • 84863012433 scopus 로고    scopus 로고
    • Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer
    • Yang H, Higgins B, Kolinsky K., et al: Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res 72:779-789, 2012
    • (2012) Cancer Res , vol.72 , pp. 779-789
    • Yang, H.1    Higgins, B.2    Kolinsky, K.3
  • 9
    • 84880211812 scopus 로고    scopus 로고
    • Implementation of timeline reforms speeds initiation of national cancer institute-sponsored trials
    • Abrams JS, Mooney MM, Zwiebel J.A., et al: Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials. J Natl Cancer Inst 105:954-959, 2013
    • (2013) J Natl Cancer Inst , vol.105 , pp. 954-959
    • Abrams, J.S.1    Mooney, M.M.2    Zwiebel, J.A.3
  • 10
    • 84864222696 scopus 로고    scopus 로고
    • No evidence for interference of H & E staining in DNA testing: Usefulness of DNA extraction from H & E-stained archival tissue sections
    • Morikawa T, Shima K, Kuchiba A., et al: No evidence for interference of H & E staining in DNA testing: Usefulness of DNA extraction from H & E-stained archival tissue sections. Am J Clin Pathol 138:122-129, 2012
    • (2012) Am J Clin Pathol , vol.138 , pp. 122-129
    • Morikawa, T.1    Shima, K.2    Kuchiba, A.3
  • 11
    • 61449259809 scopus 로고    scopus 로고
    • Epidermal growth factor receptor Abnormalities in the pathogenesis and progression of lung adenocar-cinomas
    • Tang X, Varella-Garcia M, Xavier A.C., et al: Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocar-cinomas. Cancer Prev Res (Phila) 1:192-200, 2008
    • (2008) Cancer Prev Res (Phila) , vol.1 , pp. 192-200
    • Tang, X.1    Varella-Garcia, M.2    Xavier, A.C.3
  • 12
    • 84887832513 scopus 로고    scopus 로고
    • The expression of PTEN is associated with improved prognosis in patients with ampullary adenocarci-noma after pancreaticoduodenectomy
    • Shroff S, Overman MJ, Rashid A, et al: The expression of PTEN is associated with improved prognosis in patients with ampullary adenocarci-noma after pancreaticoduodenectomy. Arch Pathol Lab Med 137:1619-1626, 2013
    • (2013) Arch Pathol Lab Med , vol.137 , pp. 1619-1626
    • Shroff, S.1    Overman, M.J.2    Rashid, A.3
  • 13
    • 79955397102 scopus 로고    scopus 로고
    • DNA methylation predicts recurrence from resected stage III proximal colon cancer
    • Ahn JB, Chung WB, Maeda O, et al: DNA methylation predicts recurrence from resected stage III proximal colon cancer. Cancer 117:1847-1854, 2011
    • (2011) Cancer , vol.117 , pp. 1847-1854
    • Ahn, J.B.1    Chung, W.B.2    Maeda, O.3
  • 14
    • 0038678777 scopus 로고    scopus 로고
    • Sensitive and quantitative universal pyrosequencing methylation analysis of CpG sites
    • Colella S, Shen L, Baggerly K.A., et al: Sensitive and quantitative universal pyrosequencing methylation analysis of CpG sites. Biotechniques 35:146-150, 2003
    • (2003) Biotechniques , vol.35 , pp. 146-150
    • Colella, S.1    Shen, L.2    Baggerly, K.A.3
  • 15
    • 0042307371 scopus 로고    scopus 로고
    • Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations
    • Dressman D, Yan H, Traverso G., et al: Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A 100: 8817-8822, 2003
    • (2003) Proc Natl Acad Sci U S A , vol.100 , pp. 8817-8822
    • Dressman, D.1    Yan, H.2    Traverso, G.3
  • 16
    • 84908219463 scopus 로고    scopus 로고
    • Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer
    • Morris V, Overman MJ, Jiang Z.Q., et al: Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer 13:164-171, 2014
    • (2014) Clin Colorectal Cancer , vol.13 , pp. 164-171
    • Morris, V.1    Overman, M.J.2    Jiang, Z.Q.3
  • 17
    • 84873360893 scopus 로고    scopus 로고
    • Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents
    • Mao M, Tian F, Mariadason J.M., et al: Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res 19:657-667, 2013
    • (2013) Clin Cancer Res , vol.19 , pp. 657-667
    • Mao, M.1    Tian, F.2    Mariadason, J.M.3
  • 18
    • 36749025213 scopus 로고    scopus 로고
    • Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer
    • Shen L, Toyota M, Kondo Y., et al: Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A 104:18654-18659, 2007
    • (2007) Proc Natl Acad Sci U S A , vol.104 , pp. 18654-18659
    • Shen, L.1    Toyota, M.2    Kondo, Y.3
  • 19
    • 20244383984 scopus 로고    scopus 로고
    • BRAF mutations in aberrant crypt foci and hyperplastic polyposis
    • Beach R, Chan AO, Wu T.T., et al: BRAF mutations in aberrant crypt foci and hyperplastic polyposis. Am J Pathol 166:1069-1075, 2005
    • (2005) Am J Pathol , vol.166 , pp. 1069-1075
    • Beach, R.1    Chan, A.O.2    Wu, T.T.3
  • 20
    • 84878066430 scopus 로고    scopus 로고
    • Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer
    • Coffee EM, Faber AC, Roper J, et al: Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer. Clin Cancer Res 19:2688-2698, 2013
    • (2013) Clin Cancer Res , vol.19 , pp. 2688-2698
    • Coffee, E.M.1    Faber, A.C.2    Roper, J.3
  • 21
    • 79959795786 scopus 로고    scopus 로고
    • Improved survival with vemurafenib in melanoma with BRAF V600E mutation
    • Chapman PB, Hauschild A, Robert C., et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516, 2011
    • (2011) N Engl J Med , vol.364 , pp. 2507-2516
    • Chapman, P.B.1    Hauschild, A.2    Robert, C.3
  • 22
    • 84861083983 scopus 로고    scopus 로고
    • Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: A phase 1 dose-escalation trial
    • Falchook GS, Long GV, Kurzrock R, et al: Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: A phase 1 dose-escalation trial. Lancet 379:1893-1901, 2012
    • (2012) Lancet , vol.379 , pp. 1893-1901
    • Falchook, G.S.1    Long, G.V.2    Kurzrock, R.3
  • 23
    • 84861863158 scopus 로고    scopus 로고
    • EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib
    • Corcoran RB, Ebi H, Turke A.B., et al: EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2:227-235, 2012
    • (2012) Cancer Discov , vol.2 , pp. 227-235
    • Corcoran, R.B.1    Ebi, H.2    Turke, A.B.3
  • 24
    • 84863230465 scopus 로고    scopus 로고
    • Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
    • Prahallad A, Sun C, Huang S., et al: Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483 100-103, 2012
    • (2012) Nature , vol.483 , pp. 100-103
    • Prahallad, A.1    Sun, C.2    Huang, S.3
  • 25
    • 77956513286 scopus 로고    scopus 로고
    • Clinica efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
    • Bollag G, Hirth P, Tsai J., et al: Clinica efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467 596-599, 2010
    • (2010) Nature , vol.467 , pp. 596-599
    • Bollag, G.1    Hirth, P.2    Tsai, J.3
  • 26
    • 84927604543 scopus 로고    scopus 로고
    • Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients
    • Yaeger R, Cercek A, O'Reilly EM, et al: Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients Clin Cancer Res 21:1313-1320, 2015
    • (2015) Clin Cancer Res , vol.21 , pp. 1313-1320
    • Yaeger, R.1    Cercek, A.2    O'Reilly, E.M.3
  • 27
    • 84919393400 scopus 로고    scopus 로고
    • Phase study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor BYL719 in patients with advanced BRAF-mutant colorectal cancer
    • Van Geel R., Elez E, Bendell J.C., et al: Phase study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor BYL719 in patients with advanced BRAF-mutant colorectal cancer. J Clin Oncol 32, 2014 (suppl; abstr 3514)
    • (2014) J Clin Oncol , vol.32
    • Van Geel, R.1    Elez, E.2    Bendell, J.C.3
  • 28
    • 0037194728 scopus 로고    scopus 로고
    • Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status
    • Rajagopalan H, Bardelli A, Lengauer C., et al Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418:934, 2002
    • (2002) Nature , vol.418 , pp. 934
    • Rajagopalan, H.1    Bardelli, A.2    Lengauer, C.3
  • 29
    • 79952463028 scopus 로고    scopus 로고
    • Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAF(V600E) mutation
    • Tie J, Gibbs P, Lipton L., et al: Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. Int J Cancer 128:2075-2084, 2011
    • (2011) Int J Cancer , vol.128 , pp. 2075-2084
    • Tie, J.1    Gibbs, P.2    Lipton, L.3
  • 30
    • 1342299898 scopus 로고    scopus 로고
    • Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas
    • Fransen K, Klintenas M, Osterstrom A., et al: Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 25:527-533, 2004
    • (2004) Carcinogenesis , vol.25 , pp. 527-533
    • Fransen, K.1    Klintenas, M.2    Osterstrom, A.3
  • 31
    • 78650303507 scopus 로고    scopus 로고
    • Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
    • Nazarian R, Shi H, Wang Q., et al: Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973-977, 2010
    • (2010) Nature , vol.468 , pp. 973-977
    • Nazarian, R.1    Shi, H.2    Wang, Q.3
  • 32
    • 84933040790 scopus 로고    scopus 로고
    • Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations
    • Ahronian LG, Sennott EM, Van Allen EM, et al: Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations. Cancer Discov 5:358-367, 2015
    • (2015) Cancer Discov , vol.5 , pp. 358-367
    • Ahronian, L.G.1    Sennott, E.M.2    Van Allen, E.M.3
  • 33
    • 84920598146 scopus 로고    scopus 로고
    • Efficacy and tolerability of vemurafenib in patients with BRAF(V600E)-positive papillary thyroid cancer: M.D. Anderson cancer center off label experience
    • Dadu R, Shah K, Busaidy N.L., et al: Efficacy and tolerability of vemurafenib in patients with BRAF(V600E)-positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience. J Clin Endocrinol Metab 100:E77-E81, 2015
    • (2015) J Clin Endocrinol Metab , vol.100 , pp. E77-E81
    • Dadu, R.1    Shah, K.2    Busaidy, N.L.3
  • 34
    • 84883879311 scopus 로고    scopus 로고
    • Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma
    • Peters S, Michielin O, Zimmermann S: Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma. J Clin Oncol 31:e341-e344, 2013
    • (2013) J Clin Oncol , vol.31 , pp. e341-e344
    • Peters, S.1    Michielin, O.2    Zimmermann, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.